Pfizer Inc to Discuss Updated Phase 1 Dose Escalation Data for ARV-471 Call Transcript
Good morning, ladies and gentlemen, and welcome to the Arvinas and Pfizer conference call. (Operator Instructions)
I would now like to turn the call over to Jeff Boyle, Vice President, Investor Relations at Arvinas. Please proceed.
Thank you, operator. Good morning, everyone, and thank you for joining us to discuss the ARV-471 dose escalation clinical trial results presented this morning at San Antonio Breast Cancer Symposium. Earlier this morning, we issued a press release highlighting these data, which can be accessed in the Investors section of our website at arvinas.com.
With me today are Arvinas President and Chief Executive Officer, John Houston; Arvinas Chief Medical Officer, Ron Peck; and Pfizer Oncology Chief Development Officer, Chris Boshoff. Ian Taylor, our Chief Scientific Officer, will join for the Q&A portion of the call.
Before we begin the call, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |